Cargando…

Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?

INTRODUCTION: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic in...

Descripción completa

Detalles Bibliográficos
Autores principales: Moghaddam, Arash, Graeser, Viola, Westhauser, Fabian, Dapunt, Ulrike, Kamradt, Till, Woerner, Stefan M, Schmidmaier, Gerhard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019425/
https://www.ncbi.nlm.nih.gov/pubmed/27660456
http://dx.doi.org/10.2147/TCRM.S107398
_version_ 1782453055121260544
author Moghaddam, Arash
Graeser, Viola
Westhauser, Fabian
Dapunt, Ulrike
Kamradt, Till
Woerner, Stefan M
Schmidmaier, Gerhard
author_facet Moghaddam, Arash
Graeser, Viola
Westhauser, Fabian
Dapunt, Ulrike
Kamradt, Till
Woerner, Stefan M
Schmidmaier, Gerhard
author_sort Moghaddam, Arash
collection PubMed
description INTRODUCTION: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic index and serious side effects; it is potentially nephrotoxic as well as ototoxic. It is not yet known if relevant gentamicin concentrations are released into the systemic circulation after implantation of gentamicin-coated nails. In order to evaluate the patients’ risks profiles and increase patient safety, we measured gentamicin levels in pre- and postoperative serum samples of patients undergoing implantation of ETN PROtect. METHODS: Twenty-five patients who received ETN PROtect between March 2012 and August 2014 were included in this study. Collection of blood samples occurred before the operation, at weeks 1–4, 3 and 6 months, and up to 1 year after the implantation. Measurement of gentamicin levels in serum samples was performed at the central laboratory of Heidelberg University Hospital. Additionally, laboratory parameters, C-reactive protein, leukocyte number, urea and creatinine concentrations were analyzed in routine controls before and after operating and assessed for systemic side effects. RESULTS: Over the course of this prospective observational study, we were able to determine that gentamicin-coated nails do not release gentamicin into the systemic circulation above the lowest detectable level of 0.2 mg/dL. There were slight increases in the mean inflammation and renal retention markers, but no gentamicin-associated side effects could be linked to implantation. Furthermore, no allergic reactions could be detected during our study. CONCLUSION: Our findings suggest that there is no relevant release of gentamicin into the systemic circulation causing a systemic effect, and serious side effects due to gentamicin-coated tibia nails should not be feared. Postoperative monitoring of renal function does not seem necessary because of the implantation of ETN PROtect.
format Online
Article
Text
id pubmed-5019425
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-50194252016-09-22 Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use? Moghaddam, Arash Graeser, Viola Westhauser, Fabian Dapunt, Ulrike Kamradt, Till Woerner, Stefan M Schmidmaier, Gerhard Ther Clin Risk Manag Original Research INTRODUCTION: Osteitis is one of the most serious complications in orthopedic surgery. Expert Tibia Nail (ETN) PROtect™ coated with a biodegradable layer of gentamicin-laden polymer was developed for prophylaxis of osteomyelitis. In systemic administration, gentamicin has only a small therapeutic index and serious side effects; it is potentially nephrotoxic as well as ototoxic. It is not yet known if relevant gentamicin concentrations are released into the systemic circulation after implantation of gentamicin-coated nails. In order to evaluate the patients’ risks profiles and increase patient safety, we measured gentamicin levels in pre- and postoperative serum samples of patients undergoing implantation of ETN PROtect. METHODS: Twenty-five patients who received ETN PROtect between March 2012 and August 2014 were included in this study. Collection of blood samples occurred before the operation, at weeks 1–4, 3 and 6 months, and up to 1 year after the implantation. Measurement of gentamicin levels in serum samples was performed at the central laboratory of Heidelberg University Hospital. Additionally, laboratory parameters, C-reactive protein, leukocyte number, urea and creatinine concentrations were analyzed in routine controls before and after operating and assessed for systemic side effects. RESULTS: Over the course of this prospective observational study, we were able to determine that gentamicin-coated nails do not release gentamicin into the systemic circulation above the lowest detectable level of 0.2 mg/dL. There were slight increases in the mean inflammation and renal retention markers, but no gentamicin-associated side effects could be linked to implantation. Furthermore, no allergic reactions could be detected during our study. CONCLUSION: Our findings suggest that there is no relevant release of gentamicin into the systemic circulation causing a systemic effect, and serious side effects due to gentamicin-coated tibia nails should not be feared. Postoperative monitoring of renal function does not seem necessary because of the implantation of ETN PROtect. Dove Medical Press 2016-09-07 /pmc/articles/PMC5019425/ /pubmed/27660456 http://dx.doi.org/10.2147/TCRM.S107398 Text en © 2016 Moghaddam et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Moghaddam, Arash
Graeser, Viola
Westhauser, Fabian
Dapunt, Ulrike
Kamradt, Till
Woerner, Stefan M
Schmidmaier, Gerhard
Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
title Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
title_full Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
title_fullStr Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
title_full_unstemmed Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
title_short Patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
title_sort patients’ safety: is there a systemic release of gentamicin by gentamicin-coated tibia nails in clinical use?
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5019425/
https://www.ncbi.nlm.nih.gov/pubmed/27660456
http://dx.doi.org/10.2147/TCRM.S107398
work_keys_str_mv AT moghaddamarash patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse
AT graeserviola patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse
AT westhauserfabian patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse
AT dapuntulrike patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse
AT kamradttill patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse
AT woernerstefanm patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse
AT schmidmaiergerhard patientssafetyisthereasystemicreleaseofgentamicinbygentamicincoatedtibianailsinclinicaluse